STAAR Surgical has upside potential following solid yearly start, says Canaccord Canaccord remains bullish on STAAR Surgical citing its solid start to 2014 and sum of the parts methodology. The firm sees a number of catalysts including gross margin expansion, revenue growth acceleration, and potential for raised guidance. Shares are Buy rated and price target increased to $21 from $20.
News For STAA From The Last 14 Days
Check below for free stories on STAA the last two weeks.